Gain Therapeutics
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.
Gain Therapeutics Company Profile: Stock Performance & Earnings
A global Swiss success story: Gain Therapeutics - Swisscore
Gain Therapeutics auf LinkedIn: We presented today new preclinical
Gain Therapeutics on X: #Leadership Spotlight: Dr. Terenzio
The Future Is Now: Matthias Alder Of Gain Therapeutics On How
Gain Therapeutics - Force Family Office
Gain Therapeutics presents hopeful data for Parkinson's, Gaucher
Gain Therapeutics and UMSOM Partner to Investigate Small Molecule
Gain Raises $40 Million in IPO, Funds Will Advance Rare Disease
Ticino-based Gain Therapeutics raises €2.5 million in Series A
Terenzio Ignoni - SVP, Quality & CMC at Gain Therapeutics
GT-02287: GCase-targeting small molecule therapy for GBA1
